1 Heparin and Low-Molecular-Weight Heparins Online Quiz Questions

UFH mainly inhibits factor Xa, while LMWHs mainly inhibit thrombin (factor IIa).

Both enhance antithrombin; UFH has substantial anti-IIa and anti-Xa activity, while LMWHs are relatively more anti-Xa selective.

Both work by directly dissolving existing clots rather than affecting clotting factors.

LMWHs inhibit both factors equally, while UFH has no meaningful effect on factor Xa.

True

False

UFH is preferred because LMWH has greater anti-IIa than anti-Xa activity.

UFH is preferred because it never requires laboratory monitoring.

UFH may be preferred when anticoagulation needs to be adjusted or stopped rapidly.

UFH is preferred because its prophylactic and treatment regimens are interchangeable.

True

False

True

False

Verify the patient, medication, concentration, dose, and route.

Assume that any heparin product can be administered at the same dose and concentration.

Assess for active bleeding and review relevant platelet trends.

Skip the medication checks if the patient has received an anticoagulant before.

Consider kidney impairment when using LMWH and check for concurrent drugs that increase bleeding risk.

Stop heparin if acute HIT is suspected or confirmed.

Continue UFH while switching to LMWH.

Initiate an appropriate non-heparin anticoagulant under clinical guidance.

Withhold all anticoagulation in every case because HIT is associated only with bleeding.

Do not simply switch from UFH to LMWH.

Intramuscular injection is preferred because it prevents bleeding.

Avoid intramuscular injection of UFH because of hematoma risk.

Use any route as long as the dose is correct.

Intramuscular injection is required whenever platelet counts are low.

Use the same concentration for every heparin product without checking the label.

Verify the prescribed drug and concentration before administration.

Choose a dose based only on whether the patient is receiving prophylaxis or treatment.

Give UFH intramuscularly to reduce the chance of a hematoma.

UFH acts mainly on factor Xa, while LMWHs act mainly on thrombin.

Both act independently of antithrombin, but LMWHs inhibit thrombin more strongly.

Both enhance antithrombin activity, and LMWHs have proportionally greater anti-Xa than anti-IIa activity.

Both enhance antithrombin activity, but LMWHs have proportionally greater anti-IIa than anti-Xa activity.

A prophylactic dose can be used for treatment if the patient has no bleeding.

Therapeutic regimens are commonly weight-based, while prophylactic regimens are often fixed-dose.

Treatment and prophylaxis use the same dosing strategy; only the product concentration changes.

A fixed prophylactic regimen should be converted to a treatment regimen without checking the protocol.

Review kidney function because severe impairment may require LMWH dose adjustment.

Ignore kidney function because it does not affect LMWH use.

Increase the LMWH dose automatically when kidney function is reduced.

Use the patient’s bleeding risk as the only factor in selecting an LMWH dose.

UFH is preferred because it has proportionally greater anti-Xa than anti-IIa activity.

LMWH is preferred because it can always be stopped more rapidly than UFH.

LMWH is preferred because UFH cannot be adjusted during an infusion.

UFH may be preferred when anticoagulation needs to be adjusted or stopped rapidly.